9,101
Views
26
CrossRef citations to date
0
Altmetric
Articles

Preparation, characterization, and evaluation of chitosan-based nanoparticles as CpG ODN carriers

, , , , & ORCID Icon
Pages 390-396 | Received 02 Jul 2018, Accepted 01 Feb 2019, Published online: 20 Feb 2019

References

  • Kitagaki K, Jain VV, Businga TR, et al. Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol. 2002;9:1260–1269.
  • Schmidt M, Anton K, Nordhaus C, et al. Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy. 2006;61:56–63.
  • Meng W, Yamazaki T, Nishida Y, et al. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human toll-like receptor 9 agonists. BMC Biotechnol. 2011;11:88.
  • Boonyo W, Junginger HE, Waranuch N, et al. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J Control Release. 2007;121:168–175.
  • Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9:55.
  • Singha S, Shao K, Ellestad KK, et al. Nanoparticles for immune stimulation against infection, cancer, and autoimmunity. ACS Nano. 2018;12:10621–10635.
  • Amidi M, Romeijn SG, Borchard G, et al. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release. 2006;111:107–116. PubMed PMID: 16380189; eng.
  • Calvo P, Remuñán-López C, Vila-Jato JL, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125–132.
  • Fan W, Yan W, Xu Z, et al. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21–27. PubMed PMID: 22014934; eng.
  • Basu A, Kunduru KR, Abtew E, et al. Polysaccharide-based conjugates for biomedical applications. Bioconjugate Chem. 2015;26:1396–1412.
  • Froidevaux V, Negrell C, Caillol S, et al. Biobased amines: from synthesis to polymers; present and future. Chem Rev. 2016;116:14181–14224.
  • Sonia TA, Sharma CP. Chitosan and its derivatives for drug delivery perspective. Chitosan for biomaterials I. In Jayakumar R, Prabaharan M, Muzzarelli R, editors. Advances in polymer science. Berlin: Springer; 2011. p. 23–53.
  • Koukaras EN, Papadimitriou SA, Bikiaris DN, et al. Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate. Mol Pharm. 2012;9:2856–2862. PubMed PMID: 22845012; eng.
  • Jonassen H, Kjoniksen AL, Hiorth M. Stability of chitosan nanoparticles cross-linked with tripolyphosphate. Biomacromolecules. 2012;13:3747–3756. PubMed PMID: 23046433; eng.
  • Chen S, Zhang H, Shi X, et al. Microfluidic generation of chitosan/CpG oligodeoxynucleotide nanoparticles with enhanced cellular uptake and immunostimulatory properties. Lab Chip. 2014;14:1842–1849.
  • Huang Y, Lapitsky Y. Salt-assisted mechanistic analysis of chitosan/tripolyphosphate micro-and nanogel formation. Biomacromolecules. 2012;13:3868–3876.
  • Huang Y, Lapitsky Y. Monovalent salt enhances colloidal stability during the formation of chitosan/tripolyphosphate microgels. Langmuir. 2011;27:10392–10399.
  • Sullivan DJ, Cruz-Romero M, Collins T, et al. Synthesis of monodisperse chitosan nanoparticles. Food Hydrocolloids. 2018;83:355–364.
  • Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomed. 2017;12:515.
  • Chen S, Zhang H, Chinnathambi S, et al. Synthesis of novel chitosan-silica/CpG oligodeoxynucleotide nanohybrids with enhanced delivery efficiency. Mater Sci Eng C Mater Biol Appl. 2013;3:3382–3388.
  • Sacco P, Brun F, Donati I, et al. On the correlation between the microscopic structure and properties of phosphate-cross-linked chitosan gels. ACS Appl Mater Interfaces. 2018;10:10761–10770.
  • Gupta GK, Agrawal DK. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs. 2010;24:225–235.
  • Suwarti S, Yamazaki T, Svetlana C, et al. Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction. Biochem Biophys Res Commun. 2013;430:1234–1239.
  • Pattani A, Patravale VB, Panicker L, et al. Immunological effects and membrane interactions of chitosan nanoparticles. Mol Pharm. 2009;6:345–352.